Stanley T. Crooke
#94,452
Most Influential Person Now
Researcher
Stanley T. Crooke's AcademicInfluence.com Rankings
Stanley T. Crookephilosophy Degrees
Philosophy
#3553
World Rank
#5715
Historical Rank
Logic
#1235
World Rank
#1929
Historical Rank
Stanley T. Crookebiology Degrees
Biology
#4457
World Rank
#6641
Historical Rank
Biochemistry
#459
World Rank
#541
Historical Rank
Download Badge
Philosophy Biology
Why Is Stanley T. Crooke Influential?
(Suggest an Edit or Addition)Stanley T. Crooke's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial (2010) (790)
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials (2016) (516)
- Cisplatin : current status and new developments (1980) (497)
- Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents (2003) (458)
- Mitomycin C: a review. (1976) (425)
- RNA-Targeted Therapeutics. (2018) (422)
- Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. (1989) (402)
- Progress in antisense technology. (2004) (398)
- Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant (1994) (390)
- Antisense Research and Applications (1993) (381)
- Molecular mechanisms of action of antisense drugs. (1999) (358)
- Cellular uptake and trafficking of antisense oligonucleotides (2017) (336)
- Antisense Drug Technology (2001) (332)
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans (2013) (330)
- Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice Published, JLR Papers in Press, January 22, 2007. (2007) (289)
- Progress in antisense oligonucleotide therapeutics. (1996) (286)
- Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. (1985) (260)
- Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. (1987) (258)
- Copper metallothionein of yeast, structure of the gene, and regulation of expression. (1984) (255)
- Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs* (2004) (254)
- Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. (1993) (251)
- Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression (2012) (251)
- Therapeutic Applications of Oligonucleotides (1992) (248)
- Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. (1989) (244)
- Therapeutic applications of oligonucleotides. (1992) (229)
- Single-Stranded siRNAs Activate RNAi in Animals (2012) (221)
- Pharmacokinetic properties of several novel oligonucleotide analogs in mice. (1996) (217)
- In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride. (1986) (216)
- Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C (1988) (209)
- Antisense Research and Application (1998) (204)
- Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. (1986) (200)
- Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells. (1988) (196)
- Human RNase III Is a 160-kDa Protein Involved in Preribosomal RNA Processing* (2000) (191)
- Rapid identification and strain-typing of respiratory pathogens for epidemic surveillance (2005) (170)
- Antisense technology: an overview and prospectus (2021) (169)
- Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. (1995) (167)
- Progress in antisense technology: the end of the beginning. (2000) (163)
- Topoisomerase IIα and Topoisomerase IIβ Genes: Characterization and Mapping to Human Chromosomes 17 and 3, Respectively (1992) (161)
- Etoposide (VP-16-213). (1979) (151)
- Determinants of aminoglycoside-binding specificity for rRNA by using mass spectrometry. (1999) (150)
- Yeast metallothionein function in metal ion detoxification. (1986) (150)
- Properties of Cloned and Expressed Human RNase H1* (1999) (149)
- Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index (2019) (149)
- Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. (1987) (146)
- Mitomycin C: Current status and new developments (1979) (145)
- Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds. (1987) (136)
- Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents. (1997) (136)
- Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B (2013) (134)
- In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. (1998) (131)
- Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages (2015) (129)
- Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B (2015) (129)
- Ubiquitin fusion augments the yield of cloned gene products in Escherichia coli. (1989) (126)
- Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts (2015) (125)
- RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus (2017) (124)
- Molecular Mechanisms of Antisense Oligonucleotides (2017) (121)
- Identification and isolation of a mammalian protein which is antigenically and functionally related to the phospholipase A2 stimulatory peptide melittin. (1987) (118)
- In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). (1982) (117)
- Purification and characterization of a phosphoinositide-specific phospholipase C from guinea pig uterus. Phosphorylation by protein kinase C in vivo. (1987) (117)
- Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. (1994) (111)
- Isolation and characterization of a cDNA clone encoding rat 5-lipoxygenase. (1988) (108)
- An overview of progress in antisense therapeutics. (1998) (108)
- Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames (2016) (108)
- Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. (1997) (107)
- Molecular mechanisms of antisense drugs: RNase H. (1998) (107)
- Cloning of a phospholipase A2-activating protein. (1991) (107)
- In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. (1995) (106)
- Rapid Identification of Emerging Pathogens: Coronavirus (2005) (102)
- Phosphorothioate modified oligonucleotide–protein interactions (2020) (102)
- Binding and Cleavage Specificities of Human Argonaute2 (2009) (102)
- Progress toward oligonucleotide therapeutics: pharmacodynamic properties (1993) (99)
- The signal transduction system of the leukotriene D4 receptor. (1989) (98)
- Structure-activity relationships of anthracyclines relative to effects on macromolecular syntheses. (1978) (98)
- Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells (2007) (98)
- Peptidoleukotrienes: distinct receptors for leukotriene C4 and D4 in the guinea-pig lung. (1983) (95)
- Chemical synthesis and expression of a cassette adapted ubiquitin gene. (1987) (93)
- Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. (1979) (93)
- Antisense strategies. (2004) (88)
- Bleomycin : current status and new developments (1978) (87)
- Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. (1986) (87)
- The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials (2017) (86)
- Phosphorothioate oligonucleotides can displace NEAT1 RNA and form nuclear paraspeckle-like structures (2014) (84)
- New Perspectives on the Structure and Function of Ubiquitin (1990) (84)
- Vasopressin induces V1 receptors to activate phosphatidylinositol- and phosphatidylcholine-specific phospholipase C and stimulates the release of arachidonic acid by at least two pathways in the smooth muscle cell line, A-10. (1988) (84)
- Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. (1987) (84)
- Deoxyribonucleic acid binding studies on several new anthracycline antitumor antibiotics. Sequence preference and structure--activity relationships of marcellomycin and its analogues as compared to adriamycin. (1979) (83)
- Antisense Drug Technology : Principles, Strategies, and Applications, Second Edition (2007) (83)
- 2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF (2015) (82)
- Antisense technology: A review (2021) (82)
- A spectroscopic investigation of the metal binding site of bleomycin A2. The Cu(II) and Zn(II) derivatives. (1978) (79)
- Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. (2002) (77)
- In vitro and in vivo pharmacologic activities of antisense oligonucleotides. (1991) (77)
- Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers (2016) (76)
- Single-strand and double-strand deoxyribonucleic acid breaks produced by several bleomycin analogues. (1981) (76)
- Regulation of 5-lipoxygenase and 5-lipoxygenase-activating protein expression in HL-60 cells. (1993) (76)
- Role of intravesical mitomycin C in management of superficial bladder tumors. (1980) (75)
- Viable RNaseH1 knockout mice show RNaseH1 is essential for R loop processing, mitochondrial and liver function (2016) (75)
- Human RNase H1 Discriminates between Subtle Variations in the Structure of the Heteroduplex Substrate (2007) (74)
- TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells (2014) (74)
- Purification, characterization, and structural properties of a single protein from rat basophilic leukemia (RBL-1) cells possessing 5-lipoxygenase and leukotriene A4 synthetase activities. (1986) (73)
- The effect of mitomycin C on superficial bladder cancer. (1981) (72)
- Viscometric and fluorometric studies of deoxyribonucleic acid interactions of several new anthracyclines. (1982) (71)
- Structural Requirements at the Catalytic Site of the Heteroduplex Substrate for Human RNase H1 Catalysis* (2004) (71)
- Cloning and expression of a yeast copper metallothionein gene. (1984) (71)
- Potential roles of antisense technology in cancer chemotherapy (2000) (70)
- Leukotriene D4 treatment of bovine aortic endothelial cells and murine smooth muscle cells in culture results in an increase in phospholipase A2 activity. (1986) (70)
- Glucocorticoid regulation of beta-adrenergic receptors in 3T3-L1 preadipocytes. (1987) (70)
- Bleomycin, a review. (1976) (68)
- Basic Principles of Antisense Therapeutics (1998) (67)
- A pharmacokinetic evaluation of 14C‐labeled afovirsen sodium in patients with genital warts (1994) (67)
- Ubiquitin-metallothionein fusion protein expression in yeast. A genetic approach for analysis of ubiquitin functions. (1988) (65)
- Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function (1977) (65)
- Molecular heterogeneity of leukotriene receptors: correlation of smooth muscle contraction and radioligand binding in guinea-pig lung. (1985) (64)
- Multiplexed screening of neutral mass-tagged RNA targets against ligand libraries with electrospray ionization FTICR MS: a paradigm for high-throughput affinity screening. (1999) (64)
- Effects of second-generation platinum analogs on isolated PM-2 DNA and their cytotoxicity in vitro and in vivo. (1980) (64)
- Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience (2019) (64)
- Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels (2017) (63)
- Efficient and specific knockdown of small non-coding RNAs in mammalian cells and in mice (2010) (63)
- Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. (1982) (63)
- Investigating the Structure of Human RNase H1 by Site-directed Mutagenesis* (2001) (63)
- Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line. (1986) (62)
- Cleavage of Single Strand RNA Adjacent to RNA-DNA Duplex Regions by Escherichia coli RNase H1* (1997) (62)
- Mammalian phosphoinositide-specific phospholipase C isoenzymes. (1989) (62)
- Interactions of 5-lipoxygenase with membranes: studies on the association of soluble enzyme with membranes and alterations in enzyme activity. (1988) (60)
- Advances in understanding the pharmacological properties of antisense oligonucleotides. (1997) (60)
- Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. (2002) (60)
- Vascular vasopressin receptors mediate phosphatidylinositol turnover and calcium efflux in an established smooth muscle cell line. (1986) (59)
- Progress in antisense therapeutics (1996) (59)
- Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2′-modifications and enhances antisense activity (2016) (58)
- Combinatorial Drug Discovery: Which Methods Will Produce the Greatest Value? (1995) (57)
- Effect of leukotrienes, bradykinin and calcium ionophore (A 23187) on bovine endothelial cells: release of prostacyclin. (1986) (57)
- Identification of metabolically stable 5′-phosphate analogs that support single-stranded siRNA activity (2015) (56)
- Low-Molecular-Weight Nuclear RNAs (2015) (56)
- Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides (2017) (55)
- Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides (2016) (55)
- Mechanism of deoxyribonucleic acid breakage induced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and copper: role for cuprous ion and oxygen free radicals. (1984) (55)
- Molecular cloning and expression of cDNA for human RNase H. (1998) (54)
- Inhibition of bleomycin-induced DNA breakage by superoxide dismutase. (1981) (54)
- Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins (2019) (53)
- SKF 104353, a high affinity antagonist for human and guinea pig lung leukotriene D4 receptor, blocked phosphatidylinositol metabolism and thromboxane synthesis induced by leukotriene D4. (1987) (53)
- Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides (2018) (52)
- Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. (1977) (52)
- Gene synthesis, expression, and processing of human ubiquitin carboxyl extension proteins. (1989) (52)
- Staurosporine inhibits protein kinase C and prevents phorbol ester-mediated leukotriene D4 receptor desensitization in RBL-1 cells. (1988) (52)
- Development of a Quantitative BRET Affinity Assay for Nucleic Acid-Protein Interactions (2016) (52)
- RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery (2016) (52)
- Identification and characterization of leukotriene D4 receptors in adult and fetal human lung. (1985) (52)
- Differential effects of manoalide on secreted and intracellular phospholipases. (1987) (51)
- Identification and Partial Purification of Human Double Strand RNase Activity (1998) (51)
- The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA (2015) (50)
- Depletion of key protein components of the RISC pathway impairs pre-ribosomal RNA processing (2011) (50)
- Leukotriene-induced hydrolysis of inositol lipids in guinea pig lung: mechanism of signal transduction for leukotriene-D4 receptors. (1987) (49)
- Interactions of gold coordination complexes with DNA. (1986) (49)
- Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms (2014) (49)
- Acute hepatotoxicity of 2′ fluoro-modified 5–10–5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins (2018) (49)
- Inhibition of phosphoinositide-specific phospholipase C by manoalide. (1987) (49)
- The Influence of Antisense Oligonucleotide-induced RNA Structure on Escherichia coli RNase H1 Activity* (1997) (48)
- The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans (2017) (48)
- Interactions of a new antitumor antibiotic BBM-928A with deoxyribonucleic acid. Bifunctional intercalative binding studied by fluorometry and viscometry. (1980) (47)
- Mechanisms of Antisense Drug Action, an Introduction (2007) (47)
- The cellular pharmacology of auranofin. (1987) (47)
- Leukotriene D4 receptor-mediated hydrolysis of phosphoinositide and mobilization of calcium in sheep tracheal smooth muscle cells. (1988) (47)
- Application of a tissue culture microtiter test for the detection of cytotoxic agents from natural products. (1985) (46)
- Genetic regulation of beta 2-adrenergic receptors in 3T3-L1 fibroblasts. (1989) (46)
- Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides (2020) (46)
- Characterization of the leukotriene D4 receptor in guinea-pig lung. (1984) (46)
- DNA breakage by tallysomycin. (1978) (46)
- The Interaction of Phosphorothioate Containing RNA Targeted Drugs with Proteins is a Critical Determinant of The Therapeutic Effects of These Agents. (2020) (46)
- Identification and characterization of leukotriene D4 receptors and signal transduction processes in rat basophilic leukemia cells. (1987) (45)
- Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals. (2013) (45)
- Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. (1992) (45)
- Progress in antisense therapeutics. (1996) (45)
- Human Dicer Binds Short Single-strand and Double-strand RNA with High Affinity and Interacts with Different Regions of the Nucleic Acids* (2009) (44)
- Human RNase H1 Is Associated with Protein P32 and Is Involved in Mitochondrial Pre-rRNA Processing (2013) (44)
- Identification and isolation of a phospholipase A2 activating protein in human rheumatoid arthritis synovial fluid: induction of eicosanoid synthesis and an inflammatory response in joints injected in vivo. (1990) (43)
- The cellular and molecular pharmacology of auranofin and related gold complexes. (1986) (43)
- Modulation of the antitumor and biochemical properties of bis(diphenylphosphine)ethane with metals. (1986) (43)
- Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides. (1995) (43)
- Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. (2001) (42)
- Thiol competition for Et3PAuS-albumin: a nonenzymatic mechanism for Et3PO formation. (1987) (42)
- Stimulation of leukotriene production and membrane translocation of 5-lipoxygenase by cross-linking of the IgE receptors in RBL-2H3 cells. (1992) (42)
- Leukotriene E4 binds specifically to LTD4 receptors in guinea pig lung membranes. (1985) (42)
- Phorbol ester-mediated inhibition of vasopressin and beta-adrenergic responses in a vascular smooth muscle cell line. (1987) (41)
- Toxicological properties of several novel oligonucleotide analogs in mice. (1997) (41)
- Solubilization of rat liver vasopressin receptors as a complex with a guanine-nucleotide-binding protein and phosphoinositide-specific phospholipase C. (1989) (41)
- Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides (2014) (41)
- Mechanisms of leukotriene E4 partial agonist activity at leukotriene D4 receptors in differentiated U-937 cells. (1989) (40)
- Antisense Drug Discovery and Development Technology Considered in a Pharmacological Context. (2020) (40)
- Regulation of ligand binding to leukotriene D4 receptors: effects of cations and guanine nucleotides. (1984) (39)
- Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells. (2013) (39)
- Origins of the increased affinity of phosphorothioate-modified therapeutic nucleic acids for proteins. (2020) (39)
- RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions (2017) (39)
- Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides (2017) (39)
- Comparative ultrastructural studies of nucleoli of tumor cells treated with adriamycin and the newer anthracyclines, carminomycin and marcellomycin. (1978) (39)
- Proof of mechanism of antisense drugs. (1996) (38)
- Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells. (2019) (37)
- Interaction of cis-diamminedichloroplatinum(II) with PM-2 DNA. (1980) (37)
- Mechanisms of Receptor Regulation (1985) (37)
- Binding of a novel dopaminergic agonist radioligand [3H]-fenoldopam (SKF 82526) to D-1 receptors in rat striatum. (1985) (37)
- An activator of protein kinase C (phorbol dibutyrate) attenuates atrial-natriuretic-factor-stimulated cyclic GMP accumulation in smooth-muscle cells. (1987) (37)
- Comparison of DNA damage and single- and double-strand breakage activities on PM-2 DNA by talisomycin and bleomycin analogs. (1980) (37)
- Islet-activating protein inhibits leukotriene D4- and leukotriene C4- but not bradykinin- or calcium ionophore-induced prostacyclin synthesis in bovine endothelial cells. (1986) (37)
- Human RNase H1 Uses One Tryptophan and Two Lysines to Position the Enzyme at the 3′-DNA/5′-RNA Terminus of the Heteroduplex Substrate* (2003) (37)
- High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl] propanoic acid. (1987) (36)
- Identification of specific binding sites for leukotriene C4 in human fetal lung. (1984) (36)
- Molecular mechanisms of action of auranofin and other gold complexes as related to their biologic activities. (1983) (35)
- Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. (1978) (35)
- Dynamic nucleoplasmic and nucleolar localization of mammalian RNase H1 in response to RNAP I transcriptional R-loops (2017) (35)
- Intermolecular cross-linking of DNA through bifunctional intercalation of an antitumor antibiotic, luzopeptin A (BBM-928A). (1983) (35)
- DNA supercoiling, shortening, and induction of single-strand regions by cis-diamminedichloroplatinum(II). (1981) (34)
- The RNase H Mechanism (2007) (34)
- Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report. (1980) (34)
- Lipoxygenases and Their Products (1991) (34)
- Leukotriene B4-induced homologous desensitization of calcium mobilization and phosphoinositide metabolism in U-937 cells. (1988) (33)
- Multiple (alpha-NH-ubiquitin)protein endoproteases in cells. (1989) (32)
- Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 ‘Slicer’ independent and can be mediated by Ago1 (2009) (32)
- Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid (1996) (31)
- Dopamine receptor agonists (1984) (31)
- Quantitative measurement of single- and double-strand breakage of DNA in Escherichia coli by the antitumor antibiotics bleomycin and talisomycin (1985) (30)
- Effects of drugs on the cell nucleus (1979) (30)
- Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. (1993) (29)
- Bifunctional intercalation of antitumor antibiotics BBM-928A and echinomycin with deoxyribonucleic acid. Effects of intercalation on deoxyribonucleic acid degradative activity of bleomycin and phleomycin. (1982) (29)
- Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides (2021) (29)
- Antileukemia (L1210) activity and toxicity of cis-dichlorodiammineplatinum(II) analogs. (1979) (29)
- Deoxyribonucleic acid breaks produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and copper. (1984) (29)
- The Positional Influence of the Helical Geometry of the Heteroduplex Substrate on Human RNase H1 Catalysis (2007) (29)
- Mitotane (o,p'-DDD). (1980) (28)
- Altered expression and transcription of the topoisomerase II gene in nitrogen mustard-resistant human cells. (1988) (28)
- Delivery of oligonucleotides and polynucleotides. (1995) (28)
- Differential effects of fluoride on adenylate cyclase activity and guanine nucleotide regulation of agonist high-affinity receptor binding. (1988) (27)
- Differential effects of aspirin and dexamethasone on phospholipase A2 and C activities and arachidonic acid release from endothelial cells in response to bradykinin and leukotriene D4. (1986) (27)
- Leukotriene D4-induced activation of protein kinase C in rat basophilic leukemia cells. (1988) (27)
- Genetic engineering and cancer chemotherapy. (1972) (27)
- Pharmacokinetics of bleomycin after im administration in man. (1981) (26)
- 4 – MITOMYCIN C—AN OVERVIEW (1981) (26)
- COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways (2018) (26)
- Interactions of bleomycin analogues with deoxyribonucleic acid and metal ions studied by fluorescence quenching. (1980) (26)
- New Insights into Cell and Membrane Transport Processes (1986) (26)
- Leukotriene D4 receptor-mediated synthesis and release of arachidonic acid metabolites in guinea pig lung: induction of thromboxane and prostacyclin biosynthesis by leukotriene D4. (1986) (25)
- Depletion of NEAT1 lncRNA attenuates nucleolar stress by releasing sequestered P54nrb and PSF to facilitate c-Myc translation (2017) (25)
- Cyclophosphamide, doxorubicin, vincristine, and low‐dose continuous infusion bleomycin in non‐Hodgkin's lymphoma: Cancer and leukemia group B study #7804 (1982) (24)
- Metallothionein turnover in mammalian cells. Implications in metal toxicity. (1986) (24)
- The iron complexes of bleomycin and tallysomycin. (1979) (24)
- Regulation of metallothionein gene expression in mammalian cells by gold compounds. (1986) (24)
- Vascular vasopressin receptors mediate inhibition of beta adrenergic receptor-induced cyclic AMP accumulation. (1986) (24)
- Cellular interactions of auranofin and a related gold complex with RAW 264.7 macrophages. (1987) (24)
- Leukotriene B4 induces formation of inositol phosphates in rat peritoneal polymorphonuclear leukocytes. (1986) (24)
- Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1 (2019) (23)
- Role of deoxyribonucleic acid topology in altering the site/sequence specificity of cleavage of deoxyribonucleic acid by bleomycin and talisomycin. (1983) (23)
- The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes. I. Characterization of triethylphosphine gold chloride-induced biochemical and morphological changes in isolated hepatocytes. (1987) (22)
- Signal transduction processes for the LTD4 receptor. (1990) (22)
- Human RNase H1 Activity Is Regulated by a Unique Redox Switch Formed between Adjacent Cysteines* (2003) (22)
- Molecular pharmacological differences between carminomycin and its analog, carminomycin-11-methyl ether, and adriamycin. (1980) (21)
- Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomes (2019) (21)
- Antisense oligonucleotides targeting human protein kinase C-alpha inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells. (1997) (21)
- Reactions of the metallodrug auranofin [(1-thio-.beta.-D-glucopyranose-2,3,4,6-tetraacetato-S)(triethylphosphine)gold] with biological ligands studied by radioisotope methodology (1986) (21)
- Transient activation of topoisomerase I in leukotriene D4 signal transduction in human cells. (1990) (21)
- RNA-Targeted Therapeutics. (2019) (20)
- Characterization of in vitro deoxyribonucleic acid breakage and cross-linking induced by bis-isopropylamine)-trans-dihydroxy-cis-dichloroplatinum(IV). (1982) (20)
- Leukotriene D4-induced homologous desensitization in basal and differentiated U-937 cells: characterization with the partial agonist leukotriene E4 and assessment of receptor reserve. (1988) (20)
- mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway (2019) (20)
- Regulation of agonist and antagonist binding to striatal D-1 dopamine receptors: studies using the selective D-1 antagonist [3H]SK&F R-83566. (1986) (20)
- Leukotriene D4 receptor-mediated phosphoinositol hydrolysis and calcium mobilization in rat basophilic leukemic cells. (1988) (20)
- Evaluating the mechanism of action of antiproliferative antisense drugs. (2000) (19)
- The antitumor effects of anthracyclines. The importance of the carbomethoxy-group at position-10 of marcellomycin and rudolfomycin. (1979) (19)
- The binding of leukotriene C4 and leukotriene D4 to membranes of a smooth muscle cell line (BC3H1) and evidence that leukotriene induced contraction in these cells is mediated by thromboxane, protein and RNA syntheses. (1985) (19)
- Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin. (1996) (19)
- Antisense technology. (1991) (19)
- Targeting of Repeated Sequences Unique to a Gene Results in Significant Increases in Antisense Oligonucleotide Potency (2014) (19)
- Comparison of bleomycin A2 and talisomycin A specific fragmentation of linear duplex DNA. (1979) (19)
- A phase I and clinical pharmacology study of intravenously administered carminomycin in cancer patients in the United States. (1982) (19)
- Effects of coordinated gold compounds on in vitro and in situ DNA replication. (1985) (18)
- U1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP (2011) (18)
- Inter-strand cross-links and single-strand breaks produced by gold(I) and gold(III) coordination complexes. (1986) (18)
- Induction of c‐fos protein by activation of vasopressin receptors in smooth muscle cells (1989) (18)
- Desensitization of vasopressin sensitive adenylate cyclase by vasopressin and phorbol esters. (1990) (18)
- Characterization of guinea pig myocardial leukotriene C4 binding sites. Regulation by cations and sulfhydryl-directed reagents. (1985) (18)
- Effects of structural modifications of antitumor antibiotics (luzopeptins) on the interactions with deoxyribonucleic acid. (1985) (18)
- Cisplatin pharmacokinetics in a patient with renal dysfunction. (1978) (18)
- Highly efficient endonucleolytic cleavage of RNA by a Cys(2)His(2) zinc-finger peptide. (1999) (18)
- Purification and characterization of a soluble phospholipase A2 from guinea pig lung. (1990) (17)
- Phase I study of oral mitomycin C. (1976) (17)
- Leukotriene D4‐induced Homologous Desensitization of Calcium Mobilization in Rat Basophilic Leukemia Cells (1988) (17)
- Immunochemical comparison of pertussis toxin substrates in brain and peripheral tissues. (1989) (17)
- Identification and characterization of vascular (V1) vasopressin receptors of an established smooth muscle cell line. (1987) (17)
- Ultrastructural study of the effect of bleomycin A2 on the nucleolus and its possibly related cytoplasmic constituents in Novikoff hepatoma cells. (1975) (17)
- 20 – CLINICAL PHARMACOLOGY OF BLEOMYCIN (1981) (16)
- Subcellular localization of leukotriene D4 receptors in sheep tracheal smooth muscle. (1988) (16)
- Identification of leukotriene D4 specific binding sites in the membrane preparation isolated from guinea pig lung. (1984) (16)
- Conjugated Antisense Oligonucleotides (1997) (16)
- Structure-activity relationships of beta-adrenergic receptor-coupled adenylate cyclase: implications of a redox mechanism for the action of agonists at beta-adrenergic receptors. (1987) (16)
- Variations in mRNA content have no effect on the potency of antisense oligonucleotides. (2000) (16)
- Expression and accurate processing of yeast penta-ubiquitin in Escherichia coli. (1987) (16)
- Leukotriene C4 ([3H]-LTC4) binding to membranes isolated from a hamster smooth muscle cell line (DDT1MF2). (1984) (16)
- Characterization of [3H]leukotriene D4 binding sites in guinea-pig ventricular myocardium. (1985) (16)
- Depletion of protein kinase C-alpha by antisense oligonucleotides alters beta-adrenergic function and reverses the phorbol ester-induced reduction of isoproterenol-induced adenosine 3'-5'-cyclic monophosphate accumulation in murine Swiss 3T3 fibroblasts. (1998) (16)
- A human ubiquitin carboxyl extension protein functions in yeast. (1990) (15)
- The transition metal binding properties of a 3rd generation bleomycin analogue, tallysomycin. (1978) (15)
- Effect of auranofin and other gold complexes on the activity of phospholipase C. (1987) (15)
- Ubiquitin function studied by disulfide engineering. (1989) (15)
- Interaction of anthracyclines with covalently closed circular DNA. (1980) (15)
- Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs (2017) (15)
- Induction of metallothionein is correlated with resistance to auranofin, a gold compound, in Chinese hamster ovary cells. (1987) (15)
- A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS (2002) (14)
- Comparison of the sequences at specific sites on DNA cleaved by the antitumor antibiotics talisomycin and bleomycin. (1982) (14)
- Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides (2018) (14)
- Acute ultrastructural effects of the antitumor antibiotic carminomycin on nucleoli of rat tissues. (1979) (14)
- Solubilization of [3H]leukotriene D4 receptor complex from guinea pig lung membranes. (1986) (14)
- Mechanisms of Regulation of Receptors and Signal Transduction Pathways for the Peptidyl Leukotrienes (1988) (14)
- Effect of anthracycline analogues on the appearance of newly synthesized total RNA and messenger RNA in the cytoplasm of erythroleukemia cells. (1982) (14)
- Uptake of Exogenous tRNA by Novikoff Hepatoma Ascites Cells∗ (1971) (14)
- The effects of prior exposure to bleomycin on the incidence of pulmonary toxicities in a group of patients with disseminated testicular carcinomas. (1978) (14)
- Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and-resistant Ehrlich ascites in vitro (2004) (14)
- Site-specific incorporation of 5′-methyl DNA enhances the therapeutic profile of gapmer ASOs (2021) (14)
- Morphological effects of mitomycin C administered intravesically to normal mice and mice with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induce bladder neoplasms. (1980) (14)
- Cellular pharmacology of mu-[1,2-bis(diphenylphosphino)ethane]bis[(1-thio-beta-D-gluco pyranosato-S)gold(I)]: a novel antitumor agent. (1986) (14)
- DNA binding studies on several new anthracycline antitumor antibiotics II. The importance of the carbomethoxy-group as position-10 of the class II anthracycline molecule. (1979) (14)
- Mobilization of extracellular Ca2+ by prostaglandin F2 alpha can be modulated by fluoride in 3T3-L1 fibroblasts. (1990) (13)
- Effects of DNA superhelical changes induced by ethidium bromide on the DNA-degrading activity of two antitumor antibiotics, bleomycin and phleomycin. (1983) (13)
- Cellular Adhesion (1994) (13)
- Solubilization of a guanine nucleotide-sensitive form of vasopressin V2 receptors from porcine kidney. (1989) (13)
- Basic Principles of Antisense Technology (2001) (12)
- Use of covalently closed circular deoxyribonucleic acid for prescreening for antitumor compounds (1979) (12)
- Glycerol-3-phospho-D-myo-inositol 4-phosphate (Gro-PIP) is an inhibitor of phosphoinositide-specific phospholipase C. (1990) (12)
- Regulation of endothelial cell adhesion molecule expression with antisense oligonucleotides. (1994) (12)
- Phorbol 12-myristate 13-acetate inhibition of leukotriene D4-induced signal transduction was rapidly reversed by staurosporine. (1988) (12)
- Chapter 3 – LEUKOTRIENE RECEPTORS AND SIGNAL TRANSDUCTION MECHANISM1 (1987) (11)
- Purification and mechanism of action of macromomycin. (1979) (11)
- Quenching of fluorescence of bleomycins by ferrous ion and its correlation with DNA-breakage activity. (1979) (11)
- siRNAs targeted to certain polyadenylation sites promote specific, RISC-independent degradation of messenger RNAs (2012) (11)
- Identification of the active species in deoxyribonucleic acid breakage induced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and copper. (1986) (11)
- Induction of functional beta-adrenergic receptors in rat aortic smooth muscle cells by sodium butyrate. (1986) (11)
- RNA helicase A is not required for RISC activity. (2013) (10)
- Specific Increase of Protein Levels by Enhancing Translation Using Antisense Oligonucleotides Targeting Upstream Open Frames. (2017) (10)
- Studies on the Structure and Function of Ubiquitin (1990) (10)
- Specificity of antisera produced against bleomycin. (1977) (10)
- Purification and characterization of predominant G-protein from bovine lung membranes. Biochemical and immunochemical comparison with Gi1 and Go purified from brain. (1989) (10)
- Regulation of topoisomerase I and II activities by cyclic nucleotide- and phospholipid-dependent protein kinases. Effects of interactions between the two transduction pathways. (1991) (10)
- Rat liver nuclear ribonucleoprotein particles: reassociation of residues with various types of RNA. (1972) (10)
- Molecular structure of the beta-adrenergic receptor. (1985) (10)
- Comparison of two radioimmunoassays and a microbiologic assay for bleomycin. (1978) (10)
- IN VITRO INTERACTION OF COVALENTLY LINKED CLOSED CIRCULAR DNA WITH THE SECOND-GENERATION PLATINUM COMPOUNDS (1980) (10)
- Ubiquitin carboxyl-terminal peptides. Substrates for ubiquitin activating enzyme. (1988) (10)
- Progress in antisense therapeutics discovery and development. (1997) (10)
- Intravesical Bleomycin in Bladder Cancer (1976) (10)
- Solubilization and reconstitution of vasopressin V1 receptors of rat liver. (1987) (10)
- Molecular mechanisms of homologous and heterologous desensitization mediated by vasopressin in smooth muscle cells. (1989) (10)
- Identification and Partial Purification of Human Double Strand RNase Activity A NOVEL TERMINATING MECHANISM FOR OLIGORIBONUCLEOTIDE ANTISENSE DRUGS* (1998) (9)
- A call to arms against ultra-rare diseases (2021) (9)
- Amino terminal amino acid sequence of macromomycin, a protein antitumor antibiotic. (1979) (9)
- Selective purification of cardiac myosin by a high-performance salicylate affinity column. (1988) (9)
- Cellular and Molecular Aspects of Inflammation (1988) (9)
- Pediatric cancer chemotherapy: an updated review (1979) (9)
- Regulatory Issues Affecting Oligonucleotides (1993) (9)
- Inhibitors of protein kinase C selectively enhanced leukotriene D4-induced calcium mobilization in differentiated U-937 cells. (1990) (9)
- Interaction of ASOs with PC4 is highly influenced by the cellular environment and ASO chemistry. (2020) (9)
- American experience with carminomycin. (1979) (9)
- Inhibition of formation of cyclic AMP and cyclic GMP by vasopressin in smooth-muscle cells is insensitive to pertussis toxin. (1988) (9)
- Alkaline phosphatase relieves desensitization of adenylate cyclase-coupled beta-adrenergic receptors in avian erythrocyte membranes. (1987) (8)
- Optimizing the impact of genomics on drug discovery and development (1998) (8)
- Interaction of covalently closed circular PM-2 DNA and hedamycin. (1979) (8)
- A review of carminomycin-a new anthracycline developed in the USSR. (1977) (8)
- Addressing the Needs of Patients with Ultra-Rare Mutations One Patient at a Time: The n-Lorem Approach. (2021) (8)
- Solid-Phase Separation of Toxic Phosphorothioate Antisense Oligonucleotide-Protein Nucleolar Aggregates Is Cytoprotective. (2021) (8)
- Regulation of beta-adrenoceptor number and subtype in 3T3-L1 preadipocytes by sodium butyrate. (1987) (8)
- Subtype-selective regulation of beta adrenergic receptor-adenylyl cyclase coupling by phorbol esters in 3T3-L1 fibroblasts. (1990) (8)
- Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors: an analysis. (1979) (8)
- Biochemical characterization of phosphorylated beta-adrenergic receptors from catecholamine-desensitized turkey erythrocytes. (1986) (8)
- Some ASOs that bind in the coding region of mRNAs and induce RNase H1 cleavage can cause increases in the pre-mRNAs that may blunt total activity (2020) (8)
- Stimulation of intracellular topoisomerase I activity by vasopressin and thrombin. Differential regulation by pertussis toxin. (1989) (8)
- A novel radiolabeled vasopressin antagonist: [3H-Phe]-desGlyd(CH2)5D-Tyr(Et)VAVP, [3H]-SK&F 101926. (1987) (8)
- Oligonucleotide therapeutics: a prospectus. (1993) (8)
- The role of phospholipase A2 activating protein (PLAP) in regulating prostanoid production in smooth muscle and endothelial cells following leukotriene D4 treatment. (1990) (8)
- Studies on the clinical pharmacology of bleomycin. (1978) (8)
- A murine model to evaluate the ability of in vitro clonogenic assays to predict the response to tumors in vivo. (1988) (7)
- New drugs and changing disease paradigms (1996) (7)
- Fluoride interaction with G-proteins. (1989) (7)
- Formation of the thiol adducts of 4'-(9-acridinylamino)methanesulfon-m-anisidide and their binding to deoxyribonucleic acid. (1986) (7)
- Evidence for tyrosine at the ligand binding center of beta-adrenergic receptors. (1986) (7)
- Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins (2021) (7)
- Vasopressin V1 receptors and inter-receptor regulation in vascular smooth muscle cells. (1988) (7)
- Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly. (2019) (7)
- Antisense therapeutics. (2019) (7)
- Chromosomal mapping of the ubiquitin gene family in Saccharomyces cerevisiae by pulsed field gel electrophoresis. (1989) (7)
- Site-specific Incorporation of 2',5'-Linked Nucleic Acids Enhances Therapeutic Profile of Antisense Oligonucleotides. (2021) (6)
- Homologous and heterologous desensitization mediated by vasopressin in smooth muscle cells. (1989) (6)
- Improved genetically modified Escherichia coli strain for prescreening antineoplastic agents (1984) (6)
- Oligonucleotide therapy. (1992) (6)
- Use of PM-2 DNA degradation as a pharmacokinetic assay for bleomycin. (1979) (6)
- New Frontiers in the Study of Gene Functions (1987) (6)
- Gapmer Antisense Oligonucleotides Targeting 5S Ribosomal RNA Can Reduce Mature 5S Ribosomal RNA by Two Mechanisms. (2020) (6)
- Carminomycin (NSC-180024): a phase I study. (1980) (6)
- Looking Back (2015) (6)
- HPLC Analysis of [3H]-Arachidonic Acid Metabolites Produced by Smooth Muscle and Endothelial Cells in Response to Leukotriene D4 (1987) (6)
- Available data from carminomycin studies in the United States: the acute intermittent intravenous schedule. (1981) (6)
- Incompatibility of aluminum-containing iv administration equipment with cis-dichlorodiammineplatinum(II) administration. (1979) (5)
- U 1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U 1 snRNP (2011) (5)
- Progress in evaluation of the potential of antisense technology. (1994) (5)
- The concept and application of antisense oligonucleotides (2001) (5)
- The antitumor effects of anthracyclines. II. The stereospecificity of the carbomethoxy group at position 10 of the class II anthracycline molecule. (1982) (5)
- Section Review Biologicals & Immunologicals Progress in the development and patenting of antisense drug discovery technology (1996) (5)
- Antisense-Mediated Reduction of Eukaryotic Noncoding RNAs (2012) (5)
- MORPHOLOGICAL MANIFESTATIONS OF CISPLATIN ANALOGS IN RATS: AN ULTRASTRUCTURAL STUDY (1980) (5)
- The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2′-O-Methyl in Selected Positions in the Antisense Oligonucleotide Enhances the Performance of RNaseH1 Active PS-ASOs (2022) (5)
- A vector for construction of gene libraries and the expression of heterologous genes in Saccharomyces cerevisiae. (1987) (4)
- Cellular and molecular pharmacology of auranofin and related gold complexes. (1986) (4)
- Hsc70 Facilitates Mannose-6-Phosphate Receptor-Mediated Intracellular Trafficking and Enhances Endosomal Release of Phosphorothioate-Modified Antisense Oligonucleotides. (2021) (4)
- A radioimmunoassay for tallysomycin. (1979) (4)
- Immuno cross-reactivity suggests that catecholamine biosynthesis enzymes and beta-adrenergic receptors may be related. (1987) (4)
- Identification of metabolically stable 5΄-phosphate analogs that support single-stranded siRNA activity (2017) (4)
- Metallothionein Turnover in Mammalian Cells (4)
- Efficient Reduction of Target RNA ’ s by siRNA and RNase H-Dependent Antisense Agents : A Comparative Analysis (2002) (4)
- Purification of guinea pig uterus phosphoinositide-specific phospholipase C. (1991) (4)
- Phase II evaluation of mitomycin C (MMC) in children with refractory solid tumors using the single high-intermittent-dose schedule. (1981) (4)
- Possible involvement of protein kinase C and cyclic AMP-dependent protein kinase in the sodium fluoride-mediated inhibition of cyclic nucleotide accumulation in smooth muscle cells. (1990) (4)
- Introduction to Clinical Oncology (2013) (4)
- Biochemical effects of bleomycin A2 on Novikoff hepatoma ascites cells. (1975) (4)
- Comments on evaluation of antisense drugs in the clinic. (2000) (4)
- Monthly Updates: Monthly Update Biologicals & Immunologicals: Progress in the development of antisense drugs (1996) (3)
- Cancer and chemotherapy (1980) (3)
- Studies on the fluorescence labeling of human red blood cell membrane ghosts with 4'-(9-acridinylamino)methanesulfon-m-anisidide. (1985) (3)
- Comprehensive Reform of the New Drug Regulatory Process (1995) (3)
- Insights into innate immune activation via PS-ASO–protein–TLR9 interactions (2022) (3)
- The Iron Bleomycins (1980) (3)
- SYNTHESIS AND PHARMACOLOGICAL CHARACTERIZATION OF 5-(2-DODECYLPHENYL)-4,6-DITHIANONANEDIOIC ACID AND 5-(2-(8-PHENYLOCTYL)PHENYL)-4,6-DITHIANONANEDIOIC ACID: PROTOTYPES OF A NOVEL CLASS OF LEUKOTRIENE ANTAGONISTS (1985) (3)
- Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index (2019) (3)
- Golgi-58K can re-localize to late endosomes upon cellular uptake of PS-ASOs and facilitates endosomal release of ASOs (2021) (3)
- Detection of a serum DNA-binding protein associated with cancer. (1982) (3)
- Effects of N-ethylmaleimide on arginine vasopressin-induced responses in an established smooth muscle cell line. (1987) (3)
- Tumorigenicity of the cyc- variant of the S49 murine lymphoma deficient in the Gs-alpha subunit of adenylate cyclase. (1988) (3)
- Inhibition of PM-2 DNA degradation by a human serum protein. (1982) (3)
- Effects of several anthracycline antitumor antibiotics on the transcriptional activity of isolated nucleoli. (1980) (3)
- RNA directed therapeutics: mechanisms and status (2013) (3)
- The Antitumor Effects of Anthracyclines (1979) (3)
- Multiple (a-NH-ubiquitin)Protein Endoproteases in Cells* (2001) (3)
- Introduction to neoplasia and antineoplastic chemotherapy (1980) (3)
- Antisense: Progress Towards Gene-Directed Cancer Therapy (2002) (3)
- Pharmacokinetics of tallysomycin and bleomycin in the beagle dog. (1979) (2)
- Islet-activating protein inhibits leukotriene D 4-and leukotriene C 4-but not bradykinin-or calcium ionophore-induced prostacyclin synthesis in bovine endothelial cells ( pertussis toxin / arachidonic acid / ADP-ribosylation / calcium ionophore A 23187 ) (2)
- Effects of Anthracyclines on Macromolecules and their Syntheses (1982) (2)
- Preparation and use of ZFY-6 zinc finger ribonuclease. (2001) (2)
- 13 – THE MOLECULAR PHARMACOLOGY OF BLEOMYCIN (1981) (2)
- Community crystal gazing (2016) (2)
- Zinostatin (neocarzinostatin). (1979) (2)
- The future of sequence-specific transcriptional inhibition. (1996) (2)
- Characterization of mammalian Gs-alpha proteins expressed in yeast. (1994) (2)
- Cyclophosphamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study No. 7804. (1982) (2)
- Letter: Intravesical bleomycin in bladder cancer. (1976) (2)
- Meeting the needs of patients with ultrarare diseases. (2022) (2)
- DNA breakage activity of the methanol extract of auromomycin (2004) (2)
- Altered actin and immunoglobulin Cμ expression in nitrogen mustard‐resistant human Burkitt lymphoma cells (1989) (2)
- NAT10 and DDX21 Proteins Interact with RNase H1 and Affect the Performance of Phosphorothioate Oligonucleotides (2022) (2)
- The 13C NMR spectra of tallysomycin and its zinc(II) complex (1980) (2)
- A comparison of the molecular pharmacology of gold and platinum complexes. (1982) (2)
- LTD4 Receptors and Signal Transduction Processes (1988) (2)
- Perinuclear positioning of endosomes can affect PS-ASO activities (2021) (1)
- Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides (2017) (1)
- Genotypic drug discovery: what does the future hold? (1999) (1)
- A surface 3'-exonuclease of Novikoff hepatoma ascites cells. (1972) (1)
- Effects of cis-diamminedichloroplatinum (CDDP) on HeLa cell non-histone nuclear proteins (2004) (1)
- High-Affinity Leukotriene Receptor Antagonists. Synthesis and Pharmacological Characterization of 2-Hydroxy-3-((2-carboxyethyl)thio)-3-(2-(8- phenyloctyl)phenyl)propanoic Acid. (1987) (1)
- Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells. (1989) (1)
- Oligonucleotide-based drugs in the control of cytokine synthesis (2000) (1)
- Phosphorylation of PI-specific phospholipase C by protein kinase C in vivo (1987) (1)
- Commentary: regulatory issues affecting oligonucleotides. (1993) (1)
- Oligonucleotide analogs might be designed to bind to m-RNA. (1997) (1)
- The Use of Covalently Closed Circular DNA to Investigate Properties of Bleomycin and Its Analogs (1979) (1)
- A Complete Outline of Fractures Including Fractures of the Skull (1951) (1)
- Characterization of arachidonate 5-lipoxygenase and leukotriene A4 synthetase from RBL-1 cells (1986) (1)
- Catecholamine-induced desensitization of adenylate cyclase coupled beta-adrenergic receptors in turkey erythrocytes: evidence for a two-step mechanism. (1987) (1)
- Pediatric cancer chemotherapy: an updated review I. Cis.Diaxnmlnedichloroplatinum II (cispla~n), (1979) (1)
- Structure-activity relationships involved in the site-specific fragmentation of linear duplex DNAs by talisomycin and bleomycin analogs (2004) (1)
- Tallysomycin, a third generation bleomycin analog. (1981) (1)
- 42 Cis-platinum based combination chemotherapy of metastatic germ cell tumors of the testes. An update (1978) (1)
- Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C. (1979) (1)
- Leukotriene Receptors and Mechanisms of Signal Transduction (1991) (1)
- Effects of structural modifications of anti-tumour antibiotics luzopeptins on cell growth and macromolecule biosynthesis. (1986) (1)
- Pulmonary toxicity studies of bleomycin tested before and after its expiration date. (1981) (1)
- THERAPEUTIC APPLICATIONS OF OLIGONUCLEOTIDES IN MEDICINE (1996) (1)
- Comparison of the response of synchronized Hela cells to talisomycin and bleomycin (2004) (1)
- Pharmacokinetics of carminomycin in dogs and humans (1981) (1)
- Development of antineoplastic agents by pharmaceutical companies. (1979) (1)
- 8 – THE ANTHRACYCLINES (1981) (1)
- Vasopressin induces release of arachidonic acid from vascular smooth muscle cells (1986) (0)
- Mechanism of action of a new bleomycin analog, tallysomycin. Abstr. (1978) (0)
- Radioimmunoassay of the bleomycin analog, tallysomycin. Abstr. (1978) (0)
- The Isis manifesto (2011) (0)
- (/sup 3/H)-SK and F 101926, a novel radiolabeled vasopressin antagonist (1986) (0)
- The Ertl-Karger Table System (1971) (0)
- Abstract 1311: Mipomersen, a First-in-Class Apo-B Synthesis Inhibitor, Lowers LDL-C in Patients With Homozygous Familial Hypercholesterolemia: Results of a Phase III Study (2009) (0)
- Frontiers in Organic Chemistry. Volume 1 Edited by Atta-ur-Rahman and Yoshihiro Hayakawa. Bentham Science Publishers, Ltd., Hilversum, The Netherlands. 2005. vi + 355 pp. 17.5 × 25 cm. ISBN 90-77527-06-0. $130.00. (2006) (0)
- Membrane-bound hormone receptor purification and characterization by HPLC (2020) (0)
- Metallothionein turnover in mammalian cell lines: implications in drug resistance (1986) (0)
- Comprar Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition | Stanley T. Crooke | 9780849387968 | Informa Healthcare (2007) (0)
- Ã-nter-molecularCross-Linking of DMA through Bifunctional Intercalation of an Antitumor Antibiotic , Luzopeptin A ( BBM-928 A ) 1 (2006) (0)
- Leukotriene formation by purified 5-lipoxygenase from rat basophilic leukemia cells (1986) (0)
- Systematic Analysis of Chemical Modifications of Phosphorothioate Antisense Oligonucleotides that Modulate Their Innate Immune Response. (2023) (0)
- Reduction efficace d'arn cibles au moyen de composes oligomeres a brin simple et double (2003) (0)
- Solubilization and reconstitution of renal vasopressin receptors (1987) (0)
- 7 – BLEOMYCIN—AN OVERVIEW (1981) (0)
- Purification and Mechanism of Action of Macromomycin 1 (2004) (0)
- Human Transcription Cofactor PC4 DNA-binding domain in complex with full phosphorothioate 5-10-5 2'-O-methyl DNA gapmer antisense oligonucleotide. (2020) (0)
- Detection of a Serum DMA-binding Protein Associated with Cancer 1 (2006) (0)
- Rapid Generation of Peptides for N-Terminal Sequence Analysis Using Immobilized Pronase (1987) (0)
- Efficient and selective knockdown of small non-coding RNAs. (2015) (0)
- DMA Supercoiling , Shortening , and Induction of Single-Strand Regions by c / s-Diamminedichloroplatinum ( ll ) 1 (2006) (0)
- Molybdate stimulates adenylate cyclase in frog erythrocyte membranes (1985) (0)
- The mechanism of bleomycin. Physical studies on a series of metallobleomycins (1978) (0)
- Evaluation of potential inhibitors of bleomycin-induced pulmonary toxicity in mice and rats. Abstr. (1980) (0)
- Inhibition of antisense oligonucleotides papillomavirus (1994) (0)
- Metallothionein function and genetic regulation in yeast (1986) (0)
- Leukotriene B/sub 4/ (LTB/sub 4/) induces formation of inositol-phosphates (IP's) in rat peritoneal polymorphonuclear leukocytes (PMN's) (1986) (0)
- DMA Breakage by Tallysomycin1 (2006) (0)
- Dibromodulcitol plus bleomycin compared with bleomycin alone in head and neck cancer (2004) (0)
- Chapter 11 – Perspectives (1991) (0)
- Induction of single strand deoxyribonucleic acid breaks by antitumor agent mamsa. Abstr. (1983) (0)
- Renovation of the new medicine regulatory process (2011) (0)
- PREFACE TO VOLUME III (1981) (0)
- Vascular Vasopressin Receptors Mediate Inhibition of Atrial Natriuretic Factor (ANF)-Induced cGMP Accumulation (1986) (0)
- Effects of DMA Superhelical Changes Induced by Ethidium Bromide on the DMA-degrading Activity of Two Antitumor Antibiotics, Bleomycin and Phleomycin1 (2006) (0)
- Regulation of the beta-adrenergic receptor-adenylate cyclase complex of 3T3-L1 fibroblasts by sodium butyrate (1986) (0)
- Hepatocyte specific RNase H1 knockout mice: Clarifying functions of mammalian RNase H1 (2016) (0)
- Modulation of topoisomerase i associated signal transduction in human cells by inhibitors of phosphorylation and poly adp ribosylation (1988) (0)
- Raynaud's phenomenon. (1979) (0)
- Molecular and chemical comparison of beta/sub 2/ and beta/sub 2/ adrenergic receptors (1986) (0)
- PREFACE TO VOLUME II (1981) (0)
- The antitumor effect of carminomycin: evidence for a mechanism of action distinct from that of adriamycin. Abstr. (1979) (0)
- Dopamine receptor agonists (1984) (0)
- Around the world in a month (2019) (0)
- RNA modifications can affect RNase H1-mediated PS-ASO activity (2022) (0)
- Treatment of Retinitis Induced by Cytomegalovirus Using Intravitreal Fomivirsen (ISIS 2922) (2020) (0)
- Use of PM2 DMA Degradation as a Pharmacokinetic Assay for Bleomycin 1 (2006) (0)
- Solubilization of Vasopressin Receptors (1991) (0)
- Contributors to Volume 5 (1991) (0)
- Butyrate modulates the expression of. beta. -adrenergic receptor subtype in 3T3-L1 cells (1986) (0)
- CHAPTER 60 – Antisense therapy (2003) (0)
- Health security preparedness and industry trends. (2015) (0)
- Reactions of the Metallodrug Auranofin ((1-Thio-β-D-glucopyranose-2,3,4,6-tetraacetato-S)(triethylphosphine)gold) with Biological Ligands Studied by Radioisotope Methodology. (1987) (0)
- Assault against cancer. (1986) (0)
- Oligonucleotide Synthesis. Methods and Applications Edited by Piet Herdewijn. Humana Press, Totowa, NJ. 2004. xi + 435 pp. 15.5 × 23.5 cm. ISBN 1-588-29-233-9. $125.00. (2005) (0)
- Comparison of DMA Damage and Single- and Double-Strand Breakage Activities on PM-2 DMA by Talisomycin and Bleomycin Analogs1 (2006) (0)
- Molecular cloning of rat phosphoinositide specific phospholipase c (1987) (0)
- Role of guanine nucleotide binding protein(s) in vasopressin-induced responses of a vascular smooth muscle cell line (1986) (0)
- Hope Lies in Dreams (2021) (0)
- Progress in molecular biology and translational science addressing the needs of nano-rare patients. (2022) (0)
- Dexamethasone regulates beta adrenergic receptors in 3T3-L1 fibroblasts (1986) (0)
- Relationship between the Intracellular Effects of Camptothecin and the Inhibition of DNA Topoisomerase I in Cultured LI 210 Cells1 (2006) (0)
- Around the world in a month (2012) (0)
- Establishing an environment in which rigorous scientific inquiry is practiced: a personal journey (2022) (0)
- SIDT2 Inhibits Phosphorothioate Antisense Oligonucleotide Activity by Regulating Cellular Localization of Lysosomes. (2022) (0)
- Leukotriene D4 Increases the Metabolism of an Inositol Tetrakisphosphate - Containing Phospholipid in U937 Cells (1990) (0)
- Studies on the oxidation-reduction properties of. beta. -adrenergic drugs. An approach to explain the differences between agonists and antagonists (1986) (0)
- Title Rapid identification of emerging pathogens : Coronavirus (2005) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stanley T. Crooke?
Stanley T. Crooke is affiliated with the following schools:
